Brickell Biotech, Inc. (BBI) |
|
0.1863 -0.021 (-9.96%)
|
05-16 08:29 |
|
Open: |
0.19 |
Pre. Close: |
0.2069 |
|
High:
|
0.21 |
Low:
|
0.185 |
|
Volume:
|
5,864,055 |
Market Cap:
|
22(M) |
|
|
|
|
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.21 - 0.21 |
0.21 - 0.21 |
|
Low:
|
0.18 - 0.18 |
0.18 - 0.18 |
|
Close:
|
0.18 - 0.19 |
0.19 - 0.19 |
|
Technical analysis |
as of: 2022-05-16 8:16:47 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.38 One year: 0.49 |
| Support: |
Support1: 0.18 Support2: 0.15 |
| Resistance: |
Resistance1: 0.33 Resistance2: 0.41 |
| Pivot: |
0.22  |
| Moving Average: |
MA(5): 0.19 MA(20): 0.24
MA(100): 0.24 MA(250): 0.47 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 4.1  %D(3): 4.3 |
| RSI: |
RSI(14): 37.5 |
| 52-week: |
High: 1.03 Low: 0.18 |
| Average Vol(K): |
3-Month: 5,593 (K) 10-Days: 8,011 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BBI ] has closed above bottom band by 7.7%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 16 May 2022
-$0.05 EPS Expected for Brickell Biotech, Inc. (NASDAQ:BBI) This Quarter - Defense World
Sat, 14 May 2022
1981 Ferrari 512 BBI "Koenig Specials" For Sale - HYPEBEAST
Thu, 12 May 2022
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Thu, 12 May 2022
Ruto-Musalia deal akin to BBI, says Azimio - The Standard
Wed, 11 May 2022
Colloidal Gold Market Size 2022 Analysis by 2029 | Key Players – BBI Solutions, Cline Scientific, Cytodiagnostics, Goldsol, Meliorum Technologies – Queen Anne and Mangolia News - Queen Anne and Mangolia News
Wed, 04 May 2022
BigBoys Industry (BBI) Up 1.03% Wednesday: What's Next? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
115 (M) |
|
% Held by Insiders
|
1.0743e+008 (%) |
|
% Held by Institutions
|
1.2 (%) |
|
Shares Short
|
1,890 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.132e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-12 |
|
Return on Assets (ttm)
|
642.2 |
|
Return on Equity (ttm)
|
-102.2 |
|
Qtrly Rev. Growth
|
327000 |
|
Gross Profit (p.s.)
|
-175 |
|
Sales Per Share
|
-5270.5 |
|
EBITDA (p.s.)
|
-2.3475e+008 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-36 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.88e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-09-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
